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Abstract. 
 
HMG1 (high mobility group 1) is a ubiqui-
tous and abundant chromatin component. However,
HMG1 can be secreted by activated macrophages and
monocytes, and can act as a mediator of inﬂammation
and endotoxic lethality. Here we document a role of
 
extracellular HMG1 in cell migration. HMG1 (and its
individual DNA-binding domains) stimulated migration
of rat smooth muscle cells in chemotaxis, chemokinesis,
and wound healing assays. HMG1 induced rapid and
transient changes of cell shape, and actin cytoskeleton
reorganization leading to an elongated polarized mor-
phology typical of motile cells. These effects were in-
hibited by antibodies directed against the receptor of
advanced glycation endproducts, indicating that the
receptor of advanced glycation endproducts is the re-
ceptor mediating the HMG1-dependent migratory re-
sponses. Pertussis toxin and the mitogen-activated
protein kinase kinase inhibitor PD98059 also blocked
 
HMG1-induced rat smooth muscle cell migration, sug-
 
gesting that a G
 
i/o
 
 protein and mitogen-activated protein
kinases are required for the HMG1 signaling pathway.
We also show that HMG1 can be released by damage or
necrosis of a variety of cell types, including endothelial
cells. Thus, HMG1 has all the hallmarks of a molecule
that can promote atherosclerosis and restenosis after
vascular damage.
Key words: atherosclerosis • chemotaxis • high mobil-
ity group 1 • receptor of advanced glycation endproducts
• smooth muscle cells
 
Introduction
 
High mobility group 1 (HMG1)
 
1
 
 protein is the archetypal
protein of the HMG-box family, which is characterized by
their DNA binding domains, called HMG boxes. HMG1 is
a small 25-kD protein of 215 amino acids with a highly
conserved sequence among mammals. The HMG1 mole-
cule is organized into three domains: two DNA binding
domains, HMG Box A and Box B, which are followed by
an acidic COOH terminus composed of 30 glutamic and
aspartic residues. The two HMG boxes, A and B, are simi-
lar 80 amino acid segments (29% identical, 65% similar)
and form an L-shaped structure (Read et al., 1993; Weir et
al., 1993; Hardman et al., 1995).
 
HMG1 has originally been identified as a ubiquitously
 
expressed, abundant nuclear protein. It is present in 
 
.
 
1
million copies per single nucleus and binds double
stranded DNA without apparent sequence specificity. In-
stead, HMG1 binds with high affinity to specific DNA
structures like kinked or bent DNA and four-way junc-
tions. However, HMG1 can be recruited to double
stranded DNA by interaction with several different
DNA-binding proteins. When bound to double stranded
DNA, it can bend it sharply, allowing the formation of
nucleoprotein complexes where several DNA-binding
proteins can contact each other while bound to their re-
spective DNA cognate sites. Accordingly, HMG1 has
been found to enhance the activity of several transcrip-
tion factors including the glucocorticoid receptor (GR),
as well as of the RAG recombinase (for review, see Bus-
tin, 1999; Bianchi and Beltrame, 2000). The phenotype of
 
Hmg1
 
2
 
/
 
2
 
 mice is in agreement with the role of HMG1 as
a regulator of transcription. Mice die shortly after birth
due to hypoglycemia and show a defect in the activation
of GR-responsive genes (Calogero et al., 1999).
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Recently, an additional role for HMG1 outside the cell
nucleus has come into focus. HMG1 was shown to be a me-
diator of endotoxin lethality as well as acute lung inflam-
mation in mice, and elevated serum levels of HMG1 in sep-
tic patients are a poor prognosis marker of survival. HMG1
can be secreted by macrophages and pituicytes in culture
in response to cytokines and bacterial endotoxin (Wang et
al., 1999a,b; Abraham et al., 2000). Such secretion is atypi-
cal: HMG1 has no leader peptide and does not travel
through the endoplasmic reticulum and the Golgi appara-
tus. Release of HMG1 from murine erythroleukemia cells
correlates with cell differentiation and the protein can be
found in a plasma membrane–associated form in these
cells (Sparatore et al., 1996; Passalacqua et al., 1997). A
protein called amphoterin, identical in sequence to HMG1,
has been described in the brain, where it is found in the nu-
cleus and cytoplasm of neuronal cells as well as in the ex-
tracellular space. Exogenously added HMG1 mediates
outgrowth of neurites, and laminin-dependent migration of
neuroblastoma and glioma cells is inhibited by antibodies
against HMG1 (Rauvala et al., 1988; Merenmies et al.,
1991; Parkkinen et al., 1993; Fages et al., 2000). Interac-
tions between HMG1 and the plasminogen activation sys-
tem, in particular tissue-type plasminogen activator results
in enhanced plasmin formation (Parkkinen and Rauvala,
1991; Parkkinen et al., 1993). Degradation of extracellular
matrix proteins is an important step in the cell migration
process, and HMG1-promoted increase of extracellular
protease activity might enable the cells to migrate.
HMG1 has been identified as one of the ligands bind-
ing to the receptor for advanced glycation endproducts
(RAGE) (Hori et al., 1995). RAGE is a multiligand recep-
tor of the immunoglobulin superfamily and is expressed
on many cell types, including endothelial cells, smooth
muscle cells, mononuclear phagocytes, and neurons (Nee-
per et al., 1992; Brett et al., 1993). It has been implicated in
several pathological processes, such as diabetes, amyloi-
doses, and atherosclerosis (reviewed in Schmidt et al.,
1999). Interaction of HMG1 and RAGE induces neurite
outgrowth, and the two proteins colocalize at the leading
edge of advancing neurites during embryonic develop-
ment (Hori et al., 1995; Huttunen et al., 1999). Tumour
growth and metastasis can be blocked by preventing the
interactions between HMG1 and RAGE. Inhibition of this
interaction suppresses also activation of mitogen-activated
protein (MAP) kinases and the expression of matrix me-
talloproteinases, molecules importantly linked to tumour
proliferation and invasion (Taguchi et al., 2000).
In this work, we document that HMG1 has a potent bio-
logical effect on smooth muscle cells (SMC), one of the cell
types where RAGE is expressed on the surface. Vascular
SMC, the most predominant cells of the larger blood ves-
sel, are located in the tunica media where they are normally
embedded in the extracellular matrix. In intact tissues,
SMC are in a contractile state or phenotype characterized
by the absence of cell division and migration. They main-
tain vessel wall rigidity and elasticity and control blood
pressure. When the endothelium is damaged, either after
mechanical or inflammatory injuries, SMC switch to a syn-
thetic phenotype and undergo cell division and cell migra-
tion. The migration of SMC from the tunica media to the
tunica intima, resulting in intimal thickening, is believed to
play an important role in the pathophysiology of many vas-
 
cular disorders, such as atherosclerosis and restenosis after
coronary angioplasty. In the synthetic state, SMC also pro-
duce higher amounts of extracellular proteinases, growth
factors, and cytokines and secrete a fibrous extracellular
matrix. After vessel wall injury, several growth factors and/
or chemoattractants released either by circulating mono-
cytes, macrophages and platelets, or by damaged endothe-
lial cells can influence the switch from the contractile to the
synthetic phenotypes and direct the migration of SMC to-
wards the vessel intima. Among these factors, bFGF ap-
pears to be one of the most important. However, SMC can
also migrate in response to angiogenic stimuli (for reviews,
see van Leeuwen, 1996; Schwartz, 1997).
Here we show that HMG1 can be released by damage or
necrosis of a variety of cell types, including endothelial
cells, and we demonstrate that HMG1 is a strong chemoat-
tractant for rat SMC (RSMC) in vitro, and that it induces
cell migration, cell shape changes, and cytoskeleton reor-
ganization. These events can be inhibited by addition of an
anti–RAGE antibody and by pertussis toxin, suggesting
that both RAGE and a G
 
i/o
 
 protein might be involved.
Furthermore, HMG1 promotes the translocation of phos-
phorylated ERK 1 and 2 into the nucleus, indicating the
involvement of the MAP kinase pathway. Therefore,
HMG1 has all the hallmarks of a molecule that can pro-
mote atherosclerosis and restenosis after vascular damage.
 
Materials and Methods
 
Materials
 
RSMC from thoracic aorta were a gift of Dr. Marco Bertulli (Bayer Re-
search Laboratory, Milan, Italy) (Degryse et al., 1999). Human umbilical
vein endothelial cells (HUVEC) were provided by Dr. Fabio Pellegatta
(San Raffaele Scientific Institute, Milan, Italy). Rat pro-urokinase was
provided by Dr. S.A. Rabbani (McGill University and Royal Victoria
Hospital, Montreal, Québec, Canada) (Degryse et al., 1999). 
 
Bordetella
pertussis
 
 toxin and its mutant were provided by Dr. M.G. Pizza (I.R.I.S.,
Siena, Italy) (Fazioli et al., 1997). Anti–RAGE antibody was a gift of Dr.
A.M. Schmidt (Columbia University, New York, NY) (Taguchi et al.,
2000). HMG1 purified from calf thymus was a gift of Jordi Bernués
(C.S.I.C., Barcelona, Spain). Collagen I and fibronectin were purchased
from Roche. The polyclonal rabbit anti–HMG1 was purchased from BD
PharMingen. The monoclonal mouse antiphosphorylated MAP kinases
(ERK 1 and 2) was from New England Biolabs, Inc. Fluorescein-conju-
gated F(ab)
 
9
 
2 fragments of anti–rabbit immunoglobulins and fluorescein-
conjugated F(ab)
 
9
 
2 fragments of anti–mouse immunoglobulins were from
Chemicon. Nonspecific rabbit polyclonal immunoglobulins, nonspecific
monoclonal mouse IgG1
 
k
 
 (MOPC-21), TRITC-conjugated phalloidin,
and fMLP (formyl-methionine-leucine-proline) were from Sigma-Aldrich.
 
Expression and Purification of HMG1 
and Derivatives
 
HMG1/M1-176 is a truncated form of HMG1 that lacks the COOH-terminal
acidic domain of the intact HMG1 molecule; for the sake of simplicity, it will
be called Box A
 
1
 
B. The plasmids pRNHMG1/M1-V176, pT7HMG1bA,
and pT7HMG1bB coding for Box A
 
1
 
B, Box A, and Box B, respectively,
have been previously described, as well as the protocols for expression and
purification of the single and double boxes (Bianchi et al., 1992).
The plasmid pT7-7-rHMG1cm used for the expression of full-length
HMG1 in bacteria was a kind gift of Prof. J.O. Thomas (Cambridge Uni-
versity, Cambridge, UK).
 
 
 
Expression and purification of full-length
HMG1 was performed in BL21(
 
2
 
) 
 
Escherichia coli
 
 strain following the
protocol of Studier and Moffatt (1986), with slight modifications: trans-
formed bacteria was grown in M9 medium supplemented with Cas-ami-
noacids 20 g/liter, glycerol 0.5%, yeast extract 5 g/liter, glucose 0.4%.
Chloramphenicol 100 
 
m
 
g/ml was used as selective agent. Temperature was
shifted from 37
 
8
 
 to 23
 
8
 
C during the 16-h induction period. 
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The procedure for the expression and purification of full-length HMG1
in yeast (
 
Pichia pastoris
 
) has been described elsewhere (Mistry et al., 1997).
 
Chemotaxis Assay
 
Chemotaxis assays were performed as previously described (Degryse et
al., 1999). In brief, modified Boyden chambers were used with filters
(5-
 
m
 
m pore size; Corning) treated with collagen I (100 
 
m
 
g/ml in 0.5 M ace-
tic acid) and fibronectin (10 
 
m
 
g/ml). 20,000–40,000 cells in serum-free
DMEM were added to the upper well of Boyden chambers. The mole-
cules to be tested were diluted in serum-free medium and added to the
lower well. Antibodies, pertussis toxin (PT), or inhibitor were added in
both wells of Boyden chambers. Overnight migration was allowed at 37
 
8
 
C.
Then, cells remaining on the upper surface of filters were scraped off and
filters were fixed in methanol and stained in a solution of 10% (wt/vol)
crystal violet in 20% (vol/vol) methanol. All experiments were performed
at least twice in triplicate. Results are the mean 
 
6 
 
SD of the number of
cells counted in 10 high power fields per filter and expressed as fold over
control. Random cell migration (i.e., migration in the absence of chemoat-
tractant) was given the arbitrary value of 100%.
 
Immunofluorescence Microscopy
 
As previously described (Degryse et al., 1999) 15,000–25,000 cells (20–40%
confluence) were seeded on glass coverslips in 2-cm
 
2
 
 wells and cultured for
24 h in DMEM plus 10% FCS, washed with PBS, and cultured for another
24 h in DMEM without FCS. In some experiments, cells were pretreated
with either antibodies (overnight), PT, or inhibitor [6 h, except with PD
98059 (1 h); New England Biolabs, Inc.]. After stimulation at 37
 
8
 
C, RSMC
were fixed for 20 min at room temperature with a solution of 3% paraform-
aldehyde, 2% sucrose in PBS, pH 7.5, followed by three washes with PBS-
BSA 0.2%. Cells were permeabilized with (mM): 20 Hepes, pH 7.4, 300
saccharose, 50 NaCl, 3 MgCl
 
2
 
, 0.5% (vol/vol) Triton X-100 for 3 min at 4
 
8
 
C,
and washed again three times with PBS-BSA 0.2%. Then, RSMC were in-
cubated with PBS-BSA 2% for 15 min at 37
 
8
 
C, with primary antibodies for
30 min at 37
 
8
 
C, washed three times with PBS-BSA 0.2%, and further incu-
bated with PBS-BSA 2% for 15 min. Cells were stained with secondary an-
tibodies and/or phalloidin for visualization of filamentous actin for 30 min
at 37
 
8
 
C. In some cases, DAPI (Roche) was used to label the nucleus. After
incubation, coverslips were washed three times with PBS-BSA 0.2%, once
with distilled water, mounted with 20% (wt/vol) Mowiol in PBS, and ana-
lyzed on a Zeiss Axiophot microscope (Carl Zeiss, Inc.). Fluorescence pho-
tographs were taken either on T-Max 400 or EPH P1600X film (Eastman
Kodak Co.) using Zeiss 40 and 100 neofluar lenses.
 
Wounding Assay
 
As previously described (Degryse et al., 1999), confluent cultures of
RSMC, grown on glass coverslips in 2-cm
 
2
 
 wells, were washed once with
PBS and FCS-starved for 24 h in serum-free DMEM. Then, single wounds
were made. The injured monolayers, washed once with PBS, were allowed
to recover for further 48 h in serum-free medium supplemented or not
with the molecule to be tested. RSMC were fixed and stained with
TRITC-phalloidin as described above. Quantification was made by taking
photographs at lower magnification and by counting the number of cells
that had migrated into the cell-free space.
 
Cell Culture and Induction of Cell Damage
 
All cells were cultured in DMEM supplemented with 10% FCS. HeLa
cells and HUVEC were induced to undergo necrosis by treatment with 5
 
m
 
M ionomycin (Sigma-Aldrich) and 20 
 
m
 
M CCCP (Sigma-Aldrich), or 6
mM deoxyglucose (Sigma-Aldrich) and 10 mM sodium azide. After 16 h
at 37
 
8
 
C, 
 
z
 
50% of the cells were necrotic. For Western blot analysis, the
medium from treated and untreated cells was collected and concentrated
50-fold using Amicon Ultrafree-MC filters; the cells were dissolved on the
plate in SDS-PAGE sample buffer. For immunofluorescence analysis, the
cells were fixed with 4% PFA, incubated with an anti–HMG1 antibody,
and stained with secondary antibody and DAPI. The permeabilization of
cells with 0.1% NP-40 was performed as described in Falciola et al. (1997).
 
Binding of Extracellular HMG1 to RSMC
 
1 million RSMC were trypsinized and incubated for 20 min at 4
 
8
 
C in 50 
 
m
 
l
PBS containing 5 
 
m
 
g BSA and 800 ng Box A
 
1
 
B (
 
z
 
2.5 
 
3
 
 10
 
13
 
 molecules).
Then, cells were pelleted and the supernatant was saved. After two
washes in 500 
 
m
 
l cold PBS, cells were resuspended in SDS-PAGE sample
buffer, heated for 5 min at 100
 
8
 
C, and loaded on a 12% tricine-SDS gel,
 
along with 20 
 
m
 
l of supernatant. The gel was blotted to an Immobilon
 
 
 
P
filter, which was stained with India ink. The amount of Box A
 
1
 
B recov-
ered in each lane was determined densitometrically, and was found to be
very similar. About 7 
 
3
 
 10
 
12
 
 molecules were associated to the cell sample,
and 
 
z
 
18 
 
3
 
 10
 
12
 
 molecules remained unbound. We confirmed this conclu-
sion by performing a binding titration of fluorescently labeled HMG1 to
RSMC using a FMAT (fluorometric microvolume assay technology) in-
strument (PE Biosystems): the binding was nonsaturable at 4
 
8
 
C.
 
Western Blots
 
Cells were trypsinized, lysed in SDS-PAGE sample buffer (50 mM Tris,
pH 6.8, 2% 2-mercaptoethanol, 4% SDS, 12% glycerol, 0.05% bromophe-
nol blue), and heated for 5 min at 100
 
8
 
C. Proteins were separated on a tri-
cine gel (Schägger and von Jagow, 1987) and blotted on a Immobilon
 
 
 
P
membrane (Millipore) using a tankblot system (Hoefer) in 25 mM Tris,
pH 7.5, 0.192 M glycine, 20% methanol. The blot was blocked for 1 h at
room temperature in 5% skim milk/TBST (20 mM Tris, pH 7.5, 137 mM
NaCl, 0.1% Tween 20), washed in TBST, and incubated for 1 h at room
temperature with the anti–HMG1 antibody in TBST/0.01% BSA. After
another wash in TBST, the blot was further incubated for 1 h with an anti–
rabbit Ig antibody (Amersham Pharmacia Biotech) in TBST/0.01% BSA.
The blot was developed after additional washes in TBST using the ECL
system (Amersham Pharmacia Biotech).
 
Statistical Analysis
 
Statistical analysis was performed with the Prism software using Student’s
 
t
 
 test for pairwise comparisons of treatments, or an ANOVA model for
the evaluation of treatments with increasing doses of a reagent.
 
Results
 
HMG1 Induces RMSC Migration
 
The chemotactic effect of HMG1 was determined with a
chemotaxis assay using modified Boyden chambers. We
tested several preparations of HMG1: HMG1 purified
from calf thymus, recombinant HMG1 expressed from 
 
E.
coli
 
, and a slightly modified HMG1 produced by the yeast
 
P. pastoris 
 
(Mistry et al., 1997).
HMG1 from calf thymus stimulated migration of RSMC
in a concentration-dependent manner, starting at doses as
low as 0.1 ng/ml and with a 2.5-fold maximal response at
100 ng/ml (Fig. 1 A). The effect of HMG1 was comparable
in amplitude to the effects of the well-characterized attrac-
tants fMLP and bFGF (Baggiolini et al., 1994; van Leeu-
wen, 1996; Degryse et al., 1999) (Fig. 1 B, and results not
shown). Polyclonal antibodies against HMG1, but not
nonspecific control antibodies, totally blocked the migra-
tory response (Fig. 1 C), showing that this was specifically
due to HMG1. These antibodies failed to alter the effect of
the chemoattractant peptide fMLP used as positive con-
trol, and they affected cell migration only marginally. Sim-
ilar results were obtained with recombinant HMG1 pro-
duced in yeast and 
 
E. coli 
 
(Fig. 1 D, and results not
shown), and anti–HMG1 antibodies abolished the effect of
recombinant HMG1 as well (not shown).
 
HMG1 Induces Time-dependent Cytoskeleton 
Reorganization and Cell Shape Changes
 
Chemoattractant-induced cell motility requires cytoskele-
ton reorganization and cell shape changes (Ridley, 1994).
Using RSMC, we have previously functionally connected
induction of cell migration and cytoskeleton reorganiza-
tion (Degryse et al., 1999). Subconfluent cultures of serum-
starved RSMC were stimulated with 100 ng/ml HMG1
from calf thymus for increasing times from 5 to 120 min, 
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and actin filaments were labeled with rhodamine-conju-
gated phalloidin. Low magnification pictures showed that
stress fibers content, cell shape and size, and cytoskeleton
organization changed within 30 min, but reversed after 120
min (Fig. 2 A). Higher magnification pictures showed that
in control conditions most RSMC exhibited numerous
stress fibers and a nonpolarized cell shape (Fig. 2 B). After
5 min, HMG1 induced a clear decrease in stress fiber con-
tent and stimulated membrane ruffling (data not shown).
Within 15–30 min, a complete change of morphology and
Figure 1. HMG1 has chemotactic activity on
RSMC. Chemotaxis assays were performed using
modified Boyden chambers. The value of 100%
corresponds to the number of cells migrating in
the absence of any stimulator (random cell migra-
tion). The data represent the mean 6 SD (n 5 3).
(A) Concentration-dependent migratory re-
sponse of RSMC to HMG1 purified from calf thy-
mus. The statistical significance of the result is
P , 0.0001 in an ANOVA model. (B) Compari-
son of the chemotactic effect of HMG1 proteins,
either purified from calf thymus or expressed in
yeast, with those of the well-characterized
chemoattractants fMLP and bFGF. All treat-
ments increase the migratory response relative to
the control (P , 0.0001 in Student’s t test). (C) Ef-
fect of anti–HMG1 antibodies on fMLP- and
HMG1-induced migration. *Treatments where
the migratory response was statistically different
from the control beyond the P 5 0.0001 limit in
Student’s t test. Treatment of RSMC with the
anti–HMG1 antibody alone, or an unspecific anti-
body, also gave statistically significant results
(0.05  ,  P , 0.01). Treatment with HMG1 plus
anti–HMG1 gave results that did not differ statis-
tically from the untreated control. (D) Concentra-
tion-dependent migratory response of RSMC to
HMG1 expressed in yeast (P. pastoris). The statis-
tical significance of the result is P , 0.0001 in an
ANOVA model.
Figure 2. Effect of HMG1 on
RSMC morphology and actin
cytoskeleton organization.
(A) Subconfluent (50–70%)
cultures of RSMC were chal-
lenged for the indicated
times with HMG1 (100 ng/
ml), either purified from calf
thymus or expressed in yeast
or E. coli as indicated. Actin
filaments were visualized us-
ing TRITC-phalloidin. (B)
Anti–HMG1 rabbit antibod-
ies, but not unspecific rabbit
antibodies, inhibit HMG1-
stimulated cytoskeleton re-
organization. RSMC were
pretreated overnight with
either anti–HMG1 (2 mg/
ml) or unspecific control
antibodies (2 mg/ml), and
then 100 ng/ml HMG1
(from calf thymus) was
added. (C) RSMC were
stimulated with 100 ng/ml
HMG1. Quantification of the actin cytoskeleton reorganization was performed by taking low-magnification photographs and
counting the cells in each state of cytoskeleton organization. Resting cells (state 1) exhibit numerous stress fibers. Nonresting cells
(state 2) show a reorganization of actin cytoskeleton: a decrease of stress fibers content, membrane ruffling, actin semi-ring with
an elongated polarized morphology characteristic of motile RSMC. 
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cytoskeleton organization had occurred: RSMC had an
elongated, polarized morphology that reflected the spatial
rearrangement of the actin cytoskeleton. Semi-ring struc-
tures of actin and membrane ruffling were observed at the
leading part of the cell. Filaments of actin were also
present flanking the nucleus and in the dragging trail.
These effects of HMG1 slowly decreased. After 1–2 h, the
stress fiber content increased back to a level similar to that
of unstimulated cells, and cell morphology returned similar
to that of unstimulated control cells.
Antibodies against HMG1 totally inhibited the cytoskel-
etal reorganization and the morphological change of
RSMC induced by HMG1 (Fig. 2 B), but did not influence
the state of organization of actin cytoskeleton of unstimu-
lated RSMC. Control antibodies were not able to inhibit
HMG1-induced reorganization of the actin filaments.
To determine whether the observed effects of HMG1 on
RSMC actually reflects a dynamic transition from resting to
motile states, we quantified the proportion of each different
state during the course of the same experiment. We took
low-magnification pictures and classified the cells in two
states: state 1 is characterized by a high number of stress fi-
bers and a nonpolarized cell shape, typical of unstimulated
cells; RSMC exhibiting a low stress fiber content, mem-
brane ruffling, actin semi-rings, or an elongated shape were
classified in state 2. Fig. 2 C shows that in unstimulated cul-
tures 60% of the cells were in state 1 and 40% in state 2.
Within 5 min after stimulation, the proportion of cells in
state 2 increased to 
 
z
 
60%, and rose to 
 
z
 
80% after 15–30
min. 1 h after the addition of HMG1, these proportions re-
versed back to the values of unstimulated cultures, with
60% of RSMC in state 1 and 40% in state 2. Afterwards,
these proportions did not change. These data show that ex-
posure to HMG1 leads to the characteristic morphological
changes and cytoskeletal rearrangements connected to cell
migration. These effects are transient and represent a
change from a resting to a migrating state.
Taken together, qualitative and quantitative data from
the chemotaxis and chemokinesis assays fully confirm that
HMG1 is a chemoattractant for RSMC.
 
Both HMG Boxes of HMG1 Have 
Chemoattractant Activity
 
To identify the chemotactically active region of HMG1,
we used truncated mutant proteins. Full-length and trun-
cated forms of HMG1 were expressed in 
 
E. coli
 
 and puri-
fied. Box A
 
1
 
B lacks the acidic COOH-terminal tail of
the intact HMG1 molecule, but bears the two DNA-
binding domains. Box A, the first DNA-binding domain
of HMG1, corresponds to amino acids 1–89; Box B, the
second DNA-binding domain, covers residues 89–176.
Full-length HMG1 from 
 
E. coli
 
 induced a dose-depen-
dent chemotactic effect on RSMC with a maximum,
about twofold above control, at 100 ng/ml. Box A
 
1
 
B
(not shown), Box A, and Box B also stimulated RSMC
migration in a concentration-dependent manner. How-
ever, these maxima were not obtained within the same
range of concentrations: the effect of Box A was maximal
at 1–10 ng/ml, whereas the chemotactic effect of Box B
peaked at 10–100 ng/ml (Fig. 3 A).
Box A
 
1
 
B, Box A, and Box B fully reproduced the ef-
fects of HMG1 on stress fiber content, membrane ruffling,
and transition to the motile state (Fig. 3 B).
Taken together, these results indicate that both DNA-
binding domains of HMG1, Box A and Box B, are chemo-
tactically active and are responsible for the migration-pro-
moting activity of full-length HMG1.
 
Wounding Experiments
 
To independently confirm the results obtained with the
chemotaxis and chemokinesis assays, we used an in vitro
wound-healing assay. Confluent monolayers of serum-
starved RSMC were wounded and then stimulated for 48 h
with HMG1, either from calf thymus or 
 
E. coli
 
. Both
HMG1 preparations increased the number of migrating
cells by 
 
z
 
1.5–2-fold (Fig. 4). We also tested Box A and Box
Figure 3. Chemotactic response of RSMC to the HMG box do-
mains of HMG1. (A) Concentration-dependent response to Box
A and Box B, both expressed in E. coli. Random cell migration is
referred to as 100% migration. The data represent the mean 6
SD (n 5 3). The statistical significance of the result is P , 0.0001
in an ANOVA model, for both Box A and Box B. (B) Effects of
full-length HMG1 expressed in E. coli (100 ng/ml), Box A1B
(100 ng/ml), Box A (10 ng/ml), or Box B (10 ng/ml) on actin cy-
toskeleton organization. Cells were incubated with the indicated
molecule for 30 min. Actin filaments were visualized using
TRITC-phalloidin.
Figure 4. Effects of HMG1 and its HMG boxes on RSMC migra-
tion into a wound. Monolayers were wounded and allowed to re-
cover for 48 h in the presence of the indicated molecules. Then,
RSMC that had migrated into the wound were counted as de-
scribed in Materials and Methods. The value of 100% corresponds
to the number of cells migrating in the absence of any stimulator
(random cell migration). The data represent the mean 6 SD (n 5
5). Statistical significance was 0.05 , P , 0.01 for treatment with
bFGF and full-length E. coli–made HMG1, 0.01 , P , 0.001 for
treatment with Box A and Box B, and 0.001 , P , 0.0001 for
treatment with calf thymus HMG1.The Journal of Cell Biology, Volume 152, 2001 1202
B (at 10 ng/ml each): both stimulated cell migration z1.8-
fold. HMG1 and its derivatives were more effective than
bFGF (50 ng/ml), which increased cell migration z1.5-fold.
HMG1 Binds to the Surface of RMSC and Activates 
Motility through the Receptor for Advanced 
Glycation Endproducts
To act as a migratory signal, HMG1 must arrive to the
membrane of responsive cells and bind to a receptor. To
test whether HMG1 binds to the surface of RSMC, we incu-
bated these cells at 48C with the Box A1B polypeptide,
which is slightly smaller than the endogenous, full-length
HMG1 and can thus be distinguished easily on SDS-PAGE
gels. From the amount of Box A1B recovered in the cell
pellet and in the supernatant (Fig. 5 A), it can be estimated
that as much as 7 million Box A1B molecules can bind to a
single RSMC (see Materials and Methods). This result dem-
onstrates that extracellular HMG1 (or truncated forms
thereof) can bind to RSMC, but most likely does not reflect
the actual receptor number. Indeed, HMG1 has already
been shown to bind to heparin and proteoglycans (Bianchi,
1988; Salmivirta et al., 1992; Nair and Jungalwala, 1997);
thus, HMG1 might also be associated with the extracellular
matrix produced by RSMC. In accordance with this hypoth-
esis, only small amounts of HMG1 bind to cells, like HeLa,
that produce little extracellular matrix (not shown).
HMG1 has been reported to bind to RAGE (Hori et al.,
1995), a multi-ligand membrane receptor that is expressed
by a vast range of cell types. RAGE is present on RSMC
(Fig. 5 B), and is thus a good candidate for the receptor
that initiates the migratory program induced by extracellu-
lar HMG1. This hypothesis was supported by the finding
that HMG1 chemotaxis was inhibited not only by anti–
HMG1 antibodies, but also by anti–RAGE antibodies
(Fig. 5 C). Furthermore, when preincubated with anti–
RAGE antibody, RSMC did not exhibit the cytoskeletal
reorganization and morphological change in response to
HMG1 migratory signal (not shown). The anti–RAGE an-
tibodies had no effect on RMSC in the absence of HMG1
and an irrelevant antibody did not block HMG1-induced
cytoskeleton reorganization.
These data indicate that the RAGE receptor is required
for the HMG1-induced responses of RSMC.
HMG1 Induces Cell Migration through a Pertussis 
Toxin-sensitive Mechanism
Since HMG1 acts as a chemoattractant for RSMC, and
many chemoattractants act via membrane receptors asso-
ciated to heterotrimeric GTP binding proteins (G pro-
teins), we tested whether G proteins could be implicated
in HMG1 signaling. A specific subclass of G proteins, the
Gi/o proteins, are inhibited by pertussis toxin and, con-
versely, PT inhibition of a certain signaling pathway re-
veals the involvement of Gi/o proteins (Baggiolini et al.,
1994; Neer, 1995; Haribabu et al., 1999). We then tested
the effect of PT on HMG1-induced RSMC migration; as a
control, we used mPT, an inactive mutant of PT that can-
not ADP-ribosylate G proteins. PT (50 ng/ml) inhibited
the chemotactic effect of HMG1 (Fig. 6), and of Box A,
Box B, and Box A1B (not shown). As expected, a similar
inhibitory effect was observed on fMLP-induced migra-
Figure 5. HMG1 binds to the surface of RSMC and stimulates
cell motility through RAGE. (A) Large amounts of HMG1 bind
to the surface of RSMC. 1 million cells were incubated at 48C
with 800 ng Box A1B and 5 mg BSA. P shows the proteins associ-
ated with the cells, after washing, and S shows 20 ml of the medium
containing unbound protein. (B) RSMC express RAGE. 1 million
cells were lysed on the plate in SDS-PAGE sample buffer, heated
for 5 min at 1008C, and then loaded on a 12% tricine gel. RAGE
was detected by Western blot with an anti–RAGE antibody. (C)
Anti–RAGE antibody inhibits HMG1-induced RSMC migration.
The value of 100% corresponds to the number of cells migrating in
the absence of any stimulator (random cell migration). The data
represent the mean 6 SD (n 5 3). Statistical significance was
0.001 , P , 0.0001 for treatment with HMG1 and HMG1 1 un-
specific antibody. Treatments with HMG1 1 anti–RAGE anti-
body, and HMG1 1 anti–HMG1 antibody, had no statistically sig-
nificant difference from the control. Treatment with anti–HMG1
and anti–RAGE antibodies alone also did not differ from the con-
trol.
Figure 6. Pertussis toxin (PT) inhibits HMG1-
induced RSMC migration and actin cytoskeleton
reorganization. (A) Chemotaxis assays. The data
represent the mean 6 SD. The value of 100%
corresponds to the number of cells migrating in
the absence of any stimulator (random cell migra-
tion). (B) Cytoskeleton reorganization. RSMC
were pretreated for 6 h either with PT or mPT
(both at 50 ng/ml), and were then stimulated (at
time 0) with either 100 ng/ml HMG1, 10 ng/ml
Box A, or 10 ng/ml Box B. The stimulation with
HMG1 was carried on for 30 min. Actin filaments
were visualized using TRITC-phalloidin.Degryse et al. Role of Extracellular HMG1 in Cell Migration 1203
tion, and no inhibition was exerted on bFGF-dependent
migration (Baggiolini et al., 1994; Bokoch, 1995; Degryse
et al., 1999) (data not shown). mPT at the same dose (50
ng/ml) had no inhibitory effect (Fig. 6), and random cell
migration was altered neither by PT nor by mPT.
These data suggest the involvement of Gi/o proteins in
the signaling pathway controlled by HMG1.
HMG1 Induces the Translocation of Phosphorylated 
ERK1 and -2 into the Nucleus of RSMC
We next investigated whether HMG1 signaling involves
the MAP kinase pathway, which is known to respond to
RAGE and to activate directly the intracellular motility
machinery. Within 30 min, HMG1 activated ERK1/2 pro-
teins in RSMC and induced their nuclear translocation
(Fig. 7). In contrast, phosphorylated ERK proteins were
hardly detectable and located in the cytoplasm, in unstim-
ulated RSMC. PD98059, the selective inhibitor of MEK,
the upstream regulator of ERK, inhibited HMG1-induced
ERK phosphorylation and nuclear translocation. HMG1-
induced RSMC migration and cytoskeleton reorganization
was also inhibited by PD98059 (Fig. 7, and results not
shown). Thus, the MAP kinase pathway appears to play an
essential role in HMG1-induced cell migration.
Extracellular HMG1 Can Originate from Damaged 
or Necrotic Cells
HMG1 is located in the nucleus of most cell types, but a
group of recent papers has shown that HMG1 can be se-
creted by macrophages stimulated with IL-1 and TNFa,
and acts extracellularly as a potent proinflammatory signal
(Wang et al., 1999a,b; Abraham et al., 2000).
We had previously shown that HMG1 is loosely bound
to chromatin (Falciola et al., 1997). Therefore, we tested
whether damaged cells, or cells undergoing necrosis, could
release HMG1 in the medium. HeLa cells or HUVEC,
which contain a significant amount of HMG1, were per-
meabilized by the addition of the nonionic detergent NP-
40 (Falciola et al., 1997). Alternatively, cells were forced
into necrosis by addition of ionomycin and the membrane
uncoupler CCCP, or by treatment with deoxyglucose and
azide. The number of cells undergoing necrosis was scored
morphologically, and when it approached 50% the super-
natant was collected. HMG1 was recovered in the super-
natant of both necrotic cells and damaged cells (Fig. 8 A).
The amount of HMG1 found in the supernatant of HU-
Figure 7. The MAP kinase pathway is involved in HMG1 signaling. RSMC, pretreated or not for 1 h with 50 mM PD98059, were stim-
ulated for 30 min with 100 ng/ml calf thymus HMG1. Cells were then stained with antibodies against phosphorylated ERK1/2 and
DAPI. A separate sample of cells were stained with TRITC-phalloidin to visualize the reorganization of the cytoskeleton.
Figure 8. HMG1 is released by necrotic and damaged cells. (A)
Western-blot analysis showing the release of HMG1 by necrotic
or permeabilized HeLa cells and HUVEC. Cells were induced
into necrosis by adding to the medium 5 mM ionomycin plus 20
mM CCCP (CCCP), or 6 mM deoxyglucose plus 10 mM sodium
azide (deoxygluc), for 16 h. Alternatively, 0.1% NP-40 was added
for 10 min. The presence of the protein in supernatants (S) and
cell pellets (P) was detected by Western blot using an anti–
HMG1 antibody. The presence of HMG1 in the left two P lanes
is due to the fact that only z50% of the treated cells underwent
necrosis. (B) Immunofluorescence performed on living and ne-
crotic HeLa cells. The cells (untreated or treated with ionomy-
cin 1 CCCP) were fixed and stained for HMG1 and DNA.The Journal of Cell Biology, Volume 152, 2001 1204
VEC, even when permeabilized with detergent, was al-
ways a fraction of the total HMG1 originally present in the
cells, because HMG1 binds to the extracellular matrix se-
creted by HUVEC (not shown).
At the single cell level, HMG1 was not associated to the
remnants of necrotic cells (Fig. 8 B). The proteins released
by damaged or necrotic cells were effective in inducing the
morphological changes associated with motility in RSMC,
and these effects were blocked by anti–HMG1 antibodies
(data not shown).
Immunohistochemistry confirmed that HMG1 is con-
tained in the nuclei of endothelial cells that line human ar-
teries (Fig. 9). Surprisingly, we found that most nuclei of
smooth muscle cells in the same arteries (Fig. 9 B, arrows)
contain an undetectable amount of HMG1. RMSC in cul-
ture in vitro also contain a very small amount of HMG1
compared with HeLa cells (Fig. 9 C).
Altogether, these data suggest that the HMG1 molecules
that signal to vascular smooth muscle cells may originate
simply by necrosis or mechanical damage of nearby cells.
Discussion
In this study, we show that the nuclear protein HMG1,
when present in the medium of rat smooth muscle cells, can
induce chemotaxis, chemokinesis, and wound healing in
vitro. We also show that HMG1 can be passively released
by damaged or necrotic cells. These elements, when taken
together, point to HMG1 as a potent mediator of vascular
remodeling after mechanical injury and/or inflammation.
HMG1 as a Chemoattractant
HMG1 is a nuclear protein that facilitates the formation
and promotes the stability of multiprotein complexes on
DNA (reviewed by Bustin, 1999; Bianchi and Beltrame,
2000). HMG1 also has a second, unrelated activity: it can
be secreted by monocytes and macrophages upon activa-
tion with IL-1 and TNFa, and acts as a potent mediator of
inflammation (Wang et al., 1999a,b; Abraham et al., 2000).
HMG1 is also present extracellularly in the brain, from
where it was purified under the name of amphoterin (Rau-
vala et al., 1988). HMG1 has been described as a chemoat-
tractant for neuronal cells, and chemoattraction and ex-
travasation of blood cells is an essential component of
inflammatory processes. For these reasons, we tested
whether HMG1 could act as a chemoattractant for RSMC,
a cell type exhibiting well-known patterns of cell migration
upon activation by a diverse set of stimulants.
To demonstrate that HMG1 is a chemoattractant, three
independent cell migration assays were used: chemotaxis,
chemokinesis, and wound healing in vitro. We also inves-
tigated whether HMG1-induced cell migration is func-
tionally connected with the characteristic morphological
changes of motile cells, which consist in the reorganization
of actin filaments and formation of an elongated polarized
shape (Degryse et al., 1999). HMG1 appears to be as po-
tent a chemoattractant as bFGF or fMLP in chemotaxis
and wound healing assays, and promotes changes of cell
shape and of cytoskeleton organization similar to those
observed with pro-urokinase (Degryse et al., 1999).
These effects are specifically due to HMG1, and not to
potential contaminants: we tested three preparations (puri-
fied from calf thymus, or produced recombinantly by yeast
and E. coli) with similar results. In addition, antibodies di-
rected against HMG1 inhibit its effects on cell migration,
whereas nonspecific control antibodies are unable to do so.
We also mapped the chemoattractant activity of HMG1
to each of its two DNA-binding domains, HMG Boxes A
and B. HMG1 is composed of the two DNA-binding do-
mains, of z80 amino acids each, and an acidic tail of 30 as-
partic and glutamic acids, connected by short linkers. The
two boxes have a low similarity at the level of primary se-
quence (29% identity), but they have a very similar ter-
tiary structure (Read et al., 1993; Weir et al., 1993; Hard-
man et al., 1995). Most likely, the molecular recognition of
the HMG boxes by the receptor that initiates the signaling
Figure 9. HMG1 is present in the nuclei of en-
dothelial cells, but not in those of vascular SMC.
(A and B). HMG1 is present in the nuclei of en-
dothelial cells, but is not detectable in the nuclei
of vascular SMC. Shown is a section of a human
pancreatic artery, stained with anti–HMG1 anti-
body and counterstained with hematoxylin, at
low (A) and high (B) magnification. The red
frame indicates the location of the area shown in
B, and the arrows point to the nuclei of SMC.
(C) Western blot analysis showing the expres-
sion level of HMG1 in RSMC in comparison to
HeLa cells. The indicated number of cells were
lysed directly in SDS-PAGE sample buffer and
loaded onto the gel. After the detection of
HMG1 (which is identical in rat and human), the
blot was stripped and subsequently stained with
antihistone antibodies to check for loading.Degryse et al. Role of Extracellular HMG1 in Cell Migration 1205
pathway for RSMC migration involves the spatially con-
served atoms of the polypeptide backbone, or the side res-
idues conserved in both boxes.
Binding to RAGE Initiates the HMG1 Signaling 
Pathway in RSMC
RAGE had already been shown to be a receptor for am-
photerin, that is molecularly identical to HMG1, in neu-
rons (Hori et al., 1995). Moreover, RAGE is involved
in inflammation (Hofmann et al., 1999), cell migration
(Taguchi et al., 2000), and diabetic atherosclerosis (Hori et
al., 1995), whereas it does not promote angiogenesis
(Taguchi et al., 2000). The experiments reported here
show that RAGE is expressed in RSMC, and anti–RAGE
antibodies inhibit the effects of HMG1 on RSMC.
When RAGE binds its ligands (advanced glycation end-
products, calgranulin/S100, b-amyloid fibrils, and ampho-
terin/HMG1), it triggers the activation of a number of key
signaling pathways, such as p21ras, NF-kB, cdc42/rac, and
MAP kinases. We confirmed that MAP kinases are re-
cruited for HMG1-induced cell migration in RSMC, as
ERK1/2 were phosphorylated and translocated to the cell
nucleus upon HMG1 stimulation, and the MEK inhibitor
PD98059 blocked cell migration.
Our data also indicate that a Gi/o protein is probably a
component of the HMG1 signaling pathway, since HMG1-
induced cell migration can be blocked by B. pertussis toxin.
Heterotrimeric G proteins are well known to be activated
in response to chemoattractants (reviewed in Dekker and
Segal, 2000; Murdoch and Finn, 2000). RAGE has been
found together with heterotrimeric G proteins in caveolae
(Lisanti et al., 1994), but so far no direct association between
RAGE and G proteins has been described in the literature.
Only one member of the immunoglobulin superfamily, the
thrombospondin receptor (also called integrin-associated
protein, IAP, or CD47), has been shown to interact directly
with a G protein (Frazier et al., 1999). On the other hand,
inhibition by pertussis toxin demonstrates a functional as-
sociation, and not necessarily a direct physical one: for ex-
ample, the urokinase receptor, which also mediates chemo-
taxis and chemokinesis, can be inhibited by pertussis toxin
without being directly associated to a G protein (Degryse
et al., 1999, 2001). The relation between RAGE and G pro-
teins will be the focus of additional research.
The Source of Extracellular HMG1
HMG1/amphoterin is present on the surface of neural
cells, and can be released by monocytes and macrophages
upon stimulation with cytokines or lipopolysaccharide,
through a nonconventional route that does not include the
endoplasmic reticulum nor the Golgi compartment (Wang
et al., 1999a). We ourselves have reproduced these find-
ings (unpublished data). Most likely, HMG1 is translo-
cated directly from the cytoplasm by a specific transporter
in a manner analogous to interleukin-1b and a small num-
ber of other secreted proteins that lack a leader peptide
(Andrei et al., 1999).
However, we also showed that HMG1 can be released in
a second, passive manner. Almost every mammalian cell
contains a large amount of HMG1 (on average, 1 million
molecules per nucleus). HMG1 is a chromatin protein, and
binds tightly to nucleosomes reconstituted from purified
DNA and histones. However, it is not tightly bound to the
chromatin of interphase cells and can be released in the ex-
tracellular medium upon detergent action (Falciola et al.,
1997), or simply when cells are mechanically damaged or
undergo necrosis (Fig. 8). Thus, HMG1 can signal the dam-
age or destruction of an individual cell to the neighboring
cells in a paracrine manner. Significantly, HMG1 binds to
heparin and proteoglycans, and thus it is not likely to travel
very far from the site of cell damage. This does not apply in
case of toxic shock, where HMG1 was found in the serum
of affected individuals: in this condition, the release of
HMG1 is massive in quantitative terms and probably sys-
temic; in fact, the appearance of HMG1 in the serum is
correlated with a negative prognosis (Wang et al., 1999a).
The cells that respond to extracellular HMG1 appear to
contain very little HMG1 themselves, and almost none in
the nucleus. RSMC contain very little HMG1 compared
with HeLa cells or endothelial cells, and what little HMG1
they contain is mainly located in the cytoplasm. Migrating
RSMC tend to concentrate HMG1 on their surface at the
leading edge of the cell (results not shown). This observa-
tion agrees with previous data showing that neuroblastoma
and glioma cells, which are responsive to HMG1, contain
little nuclear HMG1; moreover, HMG1 was localized in
growth cones during neurite outgrowth and at the leading
edge of laminin-stimulated C6 cells (Rauvala et al., 1988;
Merenmies et al., 1991; Parkkinen et al., 1993; Fages et al.,
2000). The significance of these findings is so far unclear.
However, one can speculate that HMG1-responsive cells
might contain little HMG1 to reduce the chance of inappro-
priate responses to their own HMG1. Concentration of
HMG1 at the leading edge of migrating cells might evoke
HMG1-induced responses in neighboring cells: relocation
of molecules involved in cell migration, such as integrins,
the urokinase receptor, or c-Src, is a feature of motile
RSMC (Degryse et al., 1999). Migration also involves the
activation of extracellular proteases, and the interaction be-
tween HMG1 and the plasminogen activation system (Park-
kinen and Rauvala, 1991; Parkkinen et al., 1993) might facil-
itate cell migration within the extracellular matrix.
A Potential Role for HMG1 in Vasculopathies
The responsiveness of smooth muscle cells to HMG1, the
observation that endothelial cells contain high amounts of
HMG1 while vascular SMC contain little, and the release
of HMG1 from cells undergoing mechanical damage (as
well as by activated macrophages) all point to a possible
role of HMG1 during the tissue remodeling occurring in
atherosclerosis and restenosis. Endothelial damage results
in a burst of SMC migration and proliferation (Gimbrone,
1999). Macrophages infiltrate the intima in early steps of
atherogenesis, and necrotic cells accumulate in later stages;
both macrophages and necrotic cells are expected to re-
lease HMG1 and promote SMC invasion of the intima.
RAGE has been shown to be involved in accelerated
atherosclerosis in diabetic mice deficient in apolipoprotein
E (Park et al., 1998), and the binding of advanced glycation
endproducts (AGEs) to RAGE has been considered as the
trigger for this process. However, HMG1 might be an ad-
ditional player in diabetic atherosclerosis since it might be
secreted by macrophages/foam cells and it may be released
by necrotic cells. Most interestingly, HMG1 binding toThe Journal of Cell Biology, Volume 152, 2001 1206
RAGE might be the trigger of tissue remodeling in nondi-
abetic atherosclerosis, where AGEs are not present in
pathological amounts. Our observations point to HMG1 as
a prime target in the control of vascular disease.
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